Leveraging ICH Q14 for Analytical Development
What’s new with the ICH Q14 for Analytical development?To regulate drug production, there are a multitude of documents that pharmaceutical companies can refer
read moreWhat’s new with the ICH Q14 for Analytical development?To regulate drug production, there are a multitude of documents that pharmaceutical companies can refer
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to CPHI Japan 2024
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Cell & Gene Meeting 2024 in Rome
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Advanced Therapies 2024 in London
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to RNA Leaders Europe Congress 2024 in Basel, Switzerland.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to mRNA Based Therapeutics Summint 2024 in Berlin.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami
read moreAnemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961